What's Going On With Nano-Cap Medical Device-Focused Sharps Technology On Friday?
What's Going On With Nano-Cap Medical Device-Focused Sharps Technology On Friday?
Shares of Sharps Technology Inc (NASDAQ:STSS) are trading higher on Friday, with a heavy session volume of 15.17 million.
Sharps Technology股票(NASDAQ:STSS)週五交易價格高漲，成交量達到1517萬。
On Wednesday, the medical device and pharmaceutical packaging company received two purchase orders for approximately 1 million SecureGard ultra-low waste smart safety syringes produced at Sharps' manufacturing facility in Hungary.
本週三，這家醫療器械和藥品包裝公司收到了兩份訂單，總量約爲100萬份SecureGard超低浪費智能安全注射器，這些產品是在Sharps在匈牙利的製造工廠生產的。
The first 100k syringe shipment is scheduled for the third week of July, and subsequent deliveries will be made throughout the rest of 2024.
首批10萬支注射器將在7月的第三週發貨，隨後的交貨將在2024年其餘時間內完成。
The undisclosed customer is a Swiss-based provider of cosmetic, dental, and ophthalmic injectable therapies.
未披露客戶是一家位於瑞士的化妝品、牙科和眼科注射治療服務提供商。
The initial 1mL SecureGard syringe orders are a first step in a collaboration that can leverage Sharps' technology, portfolio of drug delivery solutions, and development expertise to support the customer's growing product offerings.
首次成交的SecureGard注射器訂單是合作的第一步。此次合作將利用Sharps的技術、藥物遞送解決方案和開發專業知識爲客戶不斷增長的產品提供支持。
The need for innovative injection solutions continues to grow rapidly as injectables are the first choice for therapies as diverse as vaccines, biologics, weight loss and maintenance, ophthalmic and cosmetic applications, gene therapies, and diabetes and inflammatory disease management.
面對日益增長的需求，適用於疫苗、生物製品、減重和維持、眼科和化妝等療法的注射器繼續迅速增長，而這種創新的注射器解決方案的需求也不斷增加。同時，由於關稅、召回和來自中國的注射器質量問題的影響，Sharps的高質量智能安全注射器產品的市場需求也在不斷增加。
As a result of this market growth and the impact of the tariffs, recalls, and quality issues with Chinese-supplied syringes, Sharps is seeing increasing interest and potential demand for its high-quality smart safety syringe products.
Sharps Technology專門從事藥物遞送系統的開發和製造。該公司的SecureGard和SoloGard產品系列專注於低浪費和超低浪費注射器技術，採用積極的安全功能和世界衛生組織認可的預防重複使用措施。這些功能能保護一線醫務人員免受致命的針刺傷害，並保護公衆免受指針的危險。
Also Read: FDA Probe On China-Made Syringes: Becton Dickinson Boosts US Syringe Output Following Concerns.
FDA針對中國製造的注射器的調查：拜耳迪金森增加美國注射器產量以回應憂慮。
Sharps Technology specializes in the development and manufacturing of drug delivery systems.
Sharps Technology專門從事藥物遞送系統的開發和製造。
The company's SecureGard and SoloGard product lines focus on low-waste and ultra-low-waste syringe technologies that incorporate active safety features and World Health Organization-accredited re-use prevention measures.
該公司的SecureGard和SoloGard產品系列專注於低浪費和超低浪費注射器技術，採用積極的安全功能和世界衛生組織認可的預防重複使用措施。
These features protect front-line healthcare workers from life-threatening needle stick injuries and protect the public from the dangers of needle re-use.
這些功能能保護一線醫務人員免受致命的針刺傷害，並保護公衆免受指針的危險。
Sharps has a manufacturing facility in Hungary and is working to close on its recent asset acquisition in South Carolina to expand its manufacturing capacity in the U.S.
Sharps在匈牙利擁有一個製造工廠，並正在努力完成對南卡羅來納州的資產收購，以擴大其在美國的製造能力。
Price Action: STSS shares are up 8.76% at $0.2520 at last check Friday.
STSS股票價格在週五最後一次檢查時上漲8.76%，達到0.2520美元。
Photo via Shutterstock
圖片來自shutterstock。
Read Next
閱讀下一篇
- Largest Consumer Bank Chase Hints Increased Cost To Consumers For Everyday Banking Services.
- 最大的消費銀行JP摩根暗示將提高日常銀行服務的消費者成本。